Shortage of Dexamethasone Sodium Phosphate Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
A current shortage of Dexamethasone Sodium Phosphate Injection is affecting some presentations due to increased demand, as per FDA data from February 2019, last updated April 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Dexamethasone Sodium Phosphate Injection) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
The drug in shortage is Dexamethasone Sodium Phosphate Injection (generic name), also known under the brand name DEXAMETHASONE SODIUM PHOSPHATE. It is an injection dosage form used in various therapeutic categories including Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, and Rheumatology. The shortage status is current, with the initial posting date of February 8, 2019, and last updated on April 2, 2026.
Which Manufacturers Are Affected
- Fresenius Kabi USA, LLC:
- Unavailable: Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) with related info: Next release April 2026. Check wholesalers for inventory. Contact: 888-386-1300.
- Available: Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05, NDC 63323-165-30, NDC 63323-165-01) with related info: Check wholesalers for inventory. Contact: 888-386-1300.
- Unavailable: Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10) with related info: Expected recovery: TBD. Contact: 888-386-1300.
- Available: Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10) with related info: Check wholesalers for inventory. Contact: 888-386-1300.
- Available: Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) with related info: Check wholesalers for inventory. Contact: 888-386-1300.
- Mylan Institutional, a Viatris Company:
- Available: Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12, NDC 67457-421-30, NDC 67457-422-54). Contact: 800-796-9526.
- Available: Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10). Contact: 800-796-9526.
We understand this may be concerning for those relying on this medication, and we encourage checking with your provider for updates.
Why There's a Shortage
The shortage is due to an increase in demand for the drug. No additional details were provided.
What Patients Should Do
If you are affected, please talk to your pharmacist or healthcare provider about availability. You can also contact the manufacturers using the provided information. Remember, patients should always consult their healthcare provider for any advice and not make changes without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.